Climb Bio Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,934.63+0.45%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Climb Bio Inc

CLYMNASDAQ

Trade with Public

Trade with Public

$11.00

0.141.29%

Last update: Oct 9, 4:00 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Climb Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Climb Bio (CLYM).

Price Target Range — 6 Quarters

Analyst Consensus — 14 Analysts

1S.Buy

13Buy

Consensus RatingBuy# Analysts14Avg. Consensus PT$25Upside to Avg. PT+123.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 8, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$18→$25
Sep 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$24→$30
Sep 4, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$26→$30
Sep 3, 2026	BTIG	Julian Harrison	PT Raise	Buy	$20→$32
Sep 3, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$21→$25
Aug 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$20→$24
Aug 19, 2026	Wedbush	Laura Chico	Maintained	Outperform	$20
Aug 7, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$17→$25
Jul 27, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$17→$20
Jun 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jun 12, 2026	Wedbush	Laura Chico	Maintained	Outperform	$17
Jun 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$19→$20
Jun 8, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$35
Jun 8, 2026	BTIG	Julian Harrison	Maintained	Buy	$19
May 12, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$15→$20
May 8, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$15→$17
May 6, 2026	BTIG	Julian Harrison	PT Raise	Buy	$8→$19
May 5, 2026	Chardan Capital	Geulah Livshits	Initiate	Buy	$22
Apr 21, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$10→$18
Apr 15, 2026	Mizuho	Joseph Catanzaro	Initiate	Outperform	$18

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25

Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.

Benzinga Newsdesk

Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30

B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25

Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.

Benzinga Newsdesk